Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer.
Sakaeda K, Kurose K, Matsumura Y, Muto S, Fukuda M, Sugasaki N, Fukuda M, Takemoto S, Taniguchi H, Masuda T, Shimizu K, Kataoka Y, Irino Y, Sakai Y, Atarashi Y, Yanagida M, Hattori N, Mukae H, Nakata M, Kanda E, Oga T, Suzuki H, Oka M.
Sakaeda K, et al. Among authors: oga t.
Cancer Treat Res Commun. 2024;40:100830. doi: 10.1016/j.ctarc.2024.100830. Epub 2024 Jun 28.
Cancer Treat Res Commun. 2024.
PMID: 38964205
Free article.